Previous 10 | Next 10 |
Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therap...
Introduction Since I first wrote about Atara Biotherapeutics ( ATRA ) in October 2019, its share price has gone through a rollercoaster ride, reflecting the binary nature of investing in clinical-stage biotech companies. Share prices went as high up to over $17, before dropping by over 50%...
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Buy rating and $29 (28% upside) price target at SunTrust. More news on: Allogene Therapeutics, Inc., BridgeBio Pharma, Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in...
Introduction Since my last article on Allogene Therapeutics ( ALLO ) about 5 months ago, its share price has fallen by around 30%, largely in part due to the stock market crash driven by the COVID-19 global pandemic . Despite the progress in clinical development, strong management tea...
Humanigen ( OTCQB:HGEN ) has submitted a protocol synopsis to the FDA related to its planned Phase 3 study of lenzilumab for the prevention and treatment of cytokine storm in COVID-19 patients. More news on: Humanigen, Inc., Hoth Therapeutics, Inc., Allogene Therapeutics, Inc., Healthcar...
Introduction Sangamo Therapeutics ( SGMO ) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is best-known for...
GAITHERSBURG, Md. and SOUTH SAN FRANCISCO, Calif. , March 24, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allog...
The COVID-19 pandemic has caused the first bear market in stocks in more than a decade, and the jury's still out on how much lower the stock market could fall. Many investors wish that they could have foreseen the extent of the damage that the coronavirus outbreak would do to the global economy,...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...